Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Lilly pilots enhanced online trial information

Company aims to aid comprehension of the informed consent process

Lilly Trial View clinical study information website 

Lilly plans to make more clinical trial information available to patients online in a bid to streamline the informed consent process and, ultimately increase patient participation rates.

Time-consuming and costly, recruiting patients to take part in clinical trials has long been a problem for the industry and it is estimated that 55% of studies currently fail to meet their targets. 

Lilly's aim with its new Trial Visit Overview online feature is to provide potential trial participants with more information and at an earlier stage of studies on the informed consent process.

Writing on the company's blog Leigh Anne Naas, Lilly community manager, acknowledged the amount of information contained within this vital document can often be overwhelming for patients.

“As part of our efforts to make clinical research better, we are providing some of those study details online. The intent is for people to be able to be 'informed' before they go for that first screening visit, where they sign the 'consent'.”

Trial Visit Overview builds on information Lilly was already providing via its website, such as purpose of a study, key entry criteria and locations of participating research centres.

But the new tool, which is currently being piloted, takes that a step further by adding further details about a study's visit schedule, how long each visit might take and procedures to be conducted at each visit.

Health literacy

The pharma company was also mindful of issues patients face when it comes to health literacy.

A 2003 study found that 12% of US adults had proficient health literacy when it came to the ability to 'obtain, process, and understand basic health information and services to make appropriate health decisions'.

The US Department of Health and Human Services said over a third of adults would have difficulty with common health tasks, such as following directions on a prescription drug label or adhering to a childhood immunization schedule using a standard chart.

Approaching this issue Lilly's Naas explained: “We tried to avoid using complex medical terms and jargon and opted instead to illustrate study procedures using icons and symbols rather than words.

“We know that people's time is as precious as their health, so we designed Trial Visit Overview to help them understand how study participation may affect their daily life.”

The company hopes that by providing this information to patients upfront they will not only be more likely to say 'yes', but also to complete the study.

The pilot project has so far been added to two clinical trials, a study of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis and one of Cialis (tadalafil) in pediatric patients with pulmonary arterial hypertension (PAH).

30th January 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...